BioNTech (BNTX) Competitors

BioNTech (NASDAQ:BNTX) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Which has more volatility and risk, BNTX or GSK?

BioNTech has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

Does the media favor BNTX or GSK?

In the previous week, GSK had 15 more articles in the media than BioNTech. MarketBeat recorded 16 mentions for GSK and 1 mentions for BioNTech. GSK's average media sentiment score of 0.87 beat BioNTech's score of 0.47 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GSK	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders believe in BNTX or GSK?

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Is BNTX or GSK more profitable?

GSK has a net margin of 9.89% compared to BioNTech's net margin of -27.37%. GSK's return on equity of 48.82% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-27.37%	-3.94%	-3.41%
GSK	9.89%	48.82%	11.15%

Do analysts recommend BNTX or GSK?

BioNTech presently has a consensus price target of $137.86, indicating a potential upside of 23.31%. GSK has a consensus price target of $37.38, indicating a potential downside of 2.39%. Given BioNTech's stronger consensus rating and higher probable upside, equities analysts plainly believe BioNTech is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.83
GSK	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.11

Which has better valuation and earnings, BNTX or GSK?

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.98B	9.03	-$719.92M	-$3.40	-32.88
GSK	$40.10B	1.96	$3.29B	$1.94	19.74

Summary

GSK beats BioNTech on 10 of the 16 factors compared between the two stocks.